Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of $100 million.

Headquartered in Jerusalem, Israel, BiondVax is a clinical stage biopharmaceutical company focused on developing and, ultimately, if approved, commercializing immunomodulation therapies for infectious diseases. The company believes its vaccine candidate M-001 has the potential to become an attractive alternative to existing influenza vaccines.

The Davis Polk capital markets team included partners Michael Kaplan and Yasin Keshvargar and associates Gil Savir, Chris Van Buren and Genevieve A. Lewis. Counsel Alon Gurfinkel and associate Omer Harel provided tax advice. Members of the Davis Polk team are based in the New York, London and Washington DC offices.

Copy link to share post